about
Bezafibrate administration improves behavioral deficits and tau pathology in P301S micePotent PPARα activator derived from tomato juice, 13-oxo-9,11-octadecadienoic acid, decreases plasma and hepatic triglyceride in obese diabetic miceLigand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell growth in a mouse mammary gland cancer cell line.Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus.Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.Hypolipidemic effects of three purgative decoctions.The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemiaCopper and bezafibrate cooperate to rescue cytochrome c oxidase deficiency in cells of patients with SCO2 mutations.Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.Cholesterol and chronic hepatitis C virus infection.Do persons with diabetes benefit from combination statin and fibrate therapy?High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes.Quality and efficiency of statin prescribing across countries with a special focus on South Africa: findings and future implications.PPAR-α agonists are still on the rise: an update on clinical and experimental findings.A metabolic shift induced by a PPAR panagonist markedly reduces the effects of pathogenic mitochondrial tRNA mutations.Rationally designed PPARδ-specific agonists and their therapeutic potential for metabolic syndromeMetabolomics reveal 1-palmitoyl lysophosphatidylcholine production by peroxisome proliferator-activated receptor α.Bezafibrate causes depression of the immune response and increases the sensitivity to endotoxin in association with low level of HDL and PPARα activity in hypertensive ISIAH rats.Iron overload potentiates diet-induced hypercholesterolemia and reduces liver PPAR-α expression in hamsters.Effect of bezafibrate on monocyte cytokine release and systemic inflammation in patients with impaired fasting glucose.
P2860
Q28273620-6C46C456-88F6-4CF2-A9F2-FE4C405BD05EQ28732165-A115DC8E-4F8F-466B-AB43-479E6CA8860FQ33625872-474CE8BE-3259-4B4C-9A2E-4E2EF459A6EAQ33692555-689D1DAE-51CA-4318-8741-482848C221F0Q33890208-E3134843-884C-49CA-B495-D72FA22955C0Q34662589-70CD2820-AB75-4086-AB50-BE96C07ACAC4Q34984058-FD266F7A-35A8-4D25-95E5-1D5856F0BC3DQ35332645-2A73E349-B1C3-4895-A439-2E2661D0C3C9Q36243954-F1CC38CD-5434-4727-8668-13BD2BF0588BQ36419283-2049985C-7A13-4683-A1B0-F4D7DE0D89CBQ37891171-8E804A97-9E08-452D-B55B-D2E0F396E7EFQ37972824-6F60395E-8EC6-40C6-889E-225CC09C6A0EQ38965138-D9BAD99A-E3AD-40C2-A510-0291D1AD4B28Q39109315-B3C1E531-CB93-42E5-AE09-0AEC21A79D84Q39200940-CBC31F96-9E75-43BB-8713-70B05BDE3FC3Q39624270-286FD845-61C3-4777-93B1-94A029802226Q41677762-5FD41C64-383E-45D1-8F67-4350C3942A76Q41770947-7FC1ECC6-2BEA-4B11-9B29-852E5795FBF6Q42238786-D80A0229-E6CF-478E-93FC-71875AD1321EQ42718280-70EE5434-2A11-41FF-91AE-FFE1A3433BEFQ51385582-624114F1-03CA-4088-80D9-CB4CA15ED962
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Update on the use of fibrates: focus on bezafibrate
@ast
Update on the use of fibrates: focus on bezafibrate
@en
type
label
Update on the use of fibrates: focus on bezafibrate
@ast
Update on the use of fibrates: focus on bezafibrate
@en
prefLabel
Update on the use of fibrates: focus on bezafibrate
@ast
Update on the use of fibrates: focus on bezafibrate
@en
P2093
P2860
P921
P1476
Update on the use of fibrates: focus on bezafibrate
@en
P2093
Ilan Goldenberg
Michal Benderly
Uri Goldbourt
P2860
P304
P356
10.2147/VHRM.2008.04.01.131
P407
P577
2008-01-01T00:00:00Z